The role of muscle biopsy in the age of genetic testing

Current Opinion in Neurology

Volumn 22, Issue 5, 2009, Pages 543-553

  O'Ferrall, Erin K ^a   Sinnreich, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Molecular genetic testing; Muscle biopsy; Muscular dystrophy; Myopathology; Myopathy

Indexed keywords

DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; ENERGY METABOLISM; GENE MUTATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; MUSCLE BIOPSY; MUSCULAR DYSTROPHY; MYOPATHY; PHENOTYPE; REVIEW; SARCOLEMMA;

BIOPSY; GENETIC TESTING; HUMANS; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 70349656914     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32832ffc60     Document Type: Review

References (73)

1. Shibuya S, Wakayama Y, Inoue M, et al. Merosin (laminin-2) localization in basal lamina of normal skeletal muscle fibers and changes in plasma membrane of merosin-deficient skeletal muscle fibers. Med Electron Microsc 2003; 36:213-220.
2. Kaplan JC. The 2009 version of the gene table of neuromuscular disorders. Neuromuscul Disord 2009; 19:77-98.
3. Oliveira J, Santos R, Soares-Silva I, et al. LAMA2 gene analysis in a cohort of 26 congenital muscular dystrophy patients. Clin Genet 2008; 74:502-512.
4. Pegoraro E, Mancias P, Swerdlow SH, et al. Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol 1996; 40:782-791.
5. Muntoni F, Torelli S, Brockington M. Muscular dystrophies due to glycosylation defects. Neurotherapeutics 2008; 5:627-632.
6. Hayashi YK, Chou FL, Engvall E, et al. Mutations in the integrin alpha7 gene cause congenital myopathy. Nat Genet 1998; 19:94-97.
7. Lampe AK, Bushby KM. Collagen VI related muscle disorders. J Med Genet 2005; 42:673-685.
8. Darras BT, Krof BR, Urion DK. Dystrophinopathies. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online) December 1999 (Updated 21 March 2008). University of Washington, Seattle, USA. 1997-2009. http://www.genetests.org. [Accessed 15 April 2009]
9. Darras BT, Koenig M, Kunkel LM, et al. Direct method for prenatal diagnosis and carrier detection in Duchenne/Becker muscular dystrophy using the entire dystrophin cDNA. Am J Med Genet 1988; 29:713-726.
10. Chamberlain JS, Gibbs RA, Ranier JE, et al. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res 1988; 16:11141-11156.
11. Beggs AH, Koenig M, Boyce FM, et al. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 1990; 86:45-48.
12. Abbs S, Yau SC, Clark S, et al. A convenient multiplex PCR system for the detection of dystrophin gene deletions: a comparative analysis with cDNA hybridisation shows mistypings by both methods. J Med Genet 1991; 28: 304-311.
13. Yau SC, Bobrow M, Mathew CG, et al. Accurate diagnosis of carriers of deletions and duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis. J Med Genet 1996; 33:550-558.
14. Joncourt F, Neuhaus B, Jostarndt-Foegen K, et al. Rapid identification of female carriers of DMD/BMD by quantitative real-time PCR. Hum Mutat 2004; 23:385-391.
15. White S, Kalf M, Liu Q, et al. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet 2002; 71:365-374.
16. Gatta V, Scarciolla O, Gaspari AR, et al. Identification of deletions and duplications of the DMD gene in affected males and carrier females by multiple ligation probe amplification (MLPA). Hum Genet 2005; 117:92-98.
17. Mendell JR, Buzin CH, Feng J, et al. Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology 2001; 57:645-650.
18. Bennett RR, den Dunnen J, O'Brien KF, et al. Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing. BMC Genet 2001; 2:17.
19. Flanigan KM, von Niederhausern A, Dunn DM, et al. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet 2003; 72:931-939.
20. Hofstra RM, Mulder IM, Vossen R, et al. DGGE-based whole-gene mutation scanning of the dystrophin gene in Duchenne and Becker muscular dystrophy patients. Hum Mutat 2004; 23:57-66.
21. Zatz M, de Paula F, Starling A, et al. The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 2003; 13:532-544.
22. Aboumousa A, Hoogendijk J, Charlton R, et al. Caveolinopathy: new mutations and additional symptoms. Neuromuscul Disord 2008; 18:572-578.
23. Bruno C, Sotgia F, Gazzerro E, et al. Caveolinopathies. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). University of Washington, Seattle, USA. 1997-2009. http://www.genetests.org. [Accessed 15 April 2009]
24. Schoser B, Jacob S, Hilton-Jones D, et al. Immune-mediated rippling muscle disease with myasthenia gravis: a report of seven patients with long-term follow-up in two. Neuromuscul Disord 2009; 19:223-228.
25. Han R, Campbell KP. Dysferlin and muscle membrane repair. Curr Opin Cell Biol 2007; 19:409-416.
26. Aoki M. Dysferlinopathy. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online) 5 Februrary 2004 (updated 19 April 2006). University of Washington, Seattle, USA. 1997-2009. http://www.genetests. org. [Accessed 15 April 2009]
27. Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol 2002; 28:461-470.
28. Gallardo E, Rojas-Garcia R, de Luna N, et al. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001; 57:2136-2138.
29. Selcen D. Myofibrillar myopathies. Curr Opin Neurol 2008; 21:585-589
30. Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000; 9:2141-2147.
31. Olive M, Goldfarb LG, Shatunov A, et al. Myotilinopathy: refining the clinical and myopathological phenotype. Brain 2005; 128:2315-2326.
32. North K. What's new in congenital myopathies? Neuromuscul Disord 2008; 18:433-442.
33. Sewry CA, Jimenez-Mallebrera C, Muntoni F. Congenital myopathies. Curr Opin Neurol 2008; 21:569-575.
34. Udd B, Vihola A, Sarparanta J, et al. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology 2005; 64:636-642.
35. Haravuori H, Vihola A, Straub V, et al. Secondary calpain3 deficiency in 2qlinked muscular dystrophy: titin is the candidate gene. Neurology 2001; 56:869-877.
36. Martinsson T, Oldfors A, Darin N, et al. Autosomal dominant myopathy: missense mutation (Glu-706 - Lys) in the myosin heavy chain IIa gene. Proc Natl Acad Sci U S A 2000; 97:14614-14619.
37. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2- epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001; 29:83-87.
38. Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and frontotemporal dementia. Neuromuscul Disord 2009; 19:308-315.
39. Kramerova I, Beckmann JS, Spencer MJ. Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A). Biochim Biophys Acta 2007; 1772:128-144.
40. Fanin M, Nascimbeni AC, Angelini C. Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations. J Med Genet 2007; 44:38-43.
41. Ellis JA. Emery-Dreifuss muscular dystrophy at the nuclear envelope: 10 years on. Cell Mol Life Sci 2006; 63:2702-2709.
42. Zhang Q, Bethmann C, Worth NF, et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 2007; 16:2816-2833.
43. Karst ML, Herron KJ, Olson TM. X-linked nonsyndromic sinus node dysfunction and atrial fibrillation caused by emerin mutation. J Cardiovasc Electrophysiol 2008; 19:510-515.
44. Bouchard JP, Brais B, Brunet D, et al. Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul Disord 1997; 7 (Suppl 1): S22-S29.
45. Brais B, Rouleau GA. Oculopharyngeal muscular dystrophy. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online) 8 March 2001 (updated 22 June 2006). University of Washington, Seattle, USA. 1997-2009. http://www.genetests.org. [Accessed 15 April 15 2009]
46. Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 2007; 20:572-576.
47. Schoser BG, Schneider-Gold C, Kress W, et al. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve 2004; 29:275-281. (Pubitemid 38166851)
48. Vihola A, Bassez G, Meola G, et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 2003; 60:1854- 1857.
49. Pisani V, Panico MB, Terracciano C, et al. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. Muscle Nerve 2008; 38:1405-1411.
50. Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve 2006; 34:1-15.
51. de Greef JC, Wohlgemuth M, Chan OA, et al. Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD. Neurology 2007; 69:1018-1026.
52. van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation of D4Z4 in 4q-linked and non4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 2003; 35:315-317.
53. Arahata K, Ishihara T, Fukunaga H, et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve 1995; 2:S56-S66.
54. Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis 2008; 3:26.
55. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]- glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68:99-109.
56. Schoser BG, Muller-Hocker J, Horvath R, et al. Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol 2007; 33:544-559.
57. Nascimbeni AC, Fanin M, Tasca E, et al. Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency. Neurology 2008; 70:617-626.
58. Chamoles NA, Niizawa G, Blanco M, et al. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta 2004; 347:97-102.
59. Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002; 58:1773-1778.
60. Nadeau A, Therrien C, Karpati G, Sinnreich M. Danon disease due to a novel splice mutation in the LAMP2 gene. Muscle Nerve 2008; 37:338-342.
61. Nishino I. Autophagic vacuolar myopathy. Semin Pediatr Neurol 2006; 13:90-95.
62. Ramachandran N, Munteanu I, Wang P, et al. VMA21 deficiency causes an autophagic myopathy by compromising V-ATPase activity and lysosomal acidification. Cell 2009; 137:235-246.
63. Lucia A, Nogales-Gadea G, Perez M, et al. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol 2008; 4:568-577.
64. Orngreen MC, Schelhaas HJ, Jeppesen TD, et al. Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology 2008; 70:1876-1882.
65. Arenas J, Martin MA, Andreu AL. Glycogen storage disease type V. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online) 26 August 2005 (updated 8 May 2006). University of Washington, Seattle, USA. 1997-2009. http://www.genetests.org. [Accessed 15 April 2009]
66. Tonin P, Lewis P, Servidei S, et al. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181-185.
67. Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006; 142C:77-85.
68. Taroni F, Verderio E, Dworzak F, et al. Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat Genet 1993; 4:314-320.
69. Wiese T. Carnitine palmitoyltransferase II deficiency. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online) 30 November 2006 (updated 27 August 2004). University of Washington, Seattle, USA. 1997-2009. http://www.genetests.org. [Accessed 15 April 2009]
70. Leonard JV, Schapira AH. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 2000; 355:299-304.
71. Leonard JV, Schapira AH. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet 2000; 355:389-394.
72. Nardin RA, Johns DR. Mitochondrial dysfunction and neuromuscular disease. Muscle Nerve 2001; 24:170-191.
73. Sarnat HB, Marin-Garcia J. Pathology of mitochondrial encephalomyopathies. Can J Neurol Sci 2005; 32:152-166.